An observational study in Lung Cancer Stage IV, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 3 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 300 studies in Lung Neoplasms with a site in Italy — 87 open to participants now, 116 under way, 24 of them phase 3. Lung Neoplasms · Italy.
Among the 300 studies in Lung Neoplasms with a site in Italy, this one is the 19th largest by planned enrollment of the 91 observational ones that give a count, is one of 22 that started in 2023, is one of 91 observational ones, reaches primary completion later than 44 of the 115 other live ones, and was the 218th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →87 of the 300 studies in Lung Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
Casa di Cura Dott. Pederzoli · Sites in Italy
Ages 18+
European Institute of Oncology · Sites in Italy
Ages 18+ · Healthy volunteers
SystImmune Inc. · Sites in Italy, United States, Australia and 13 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Italy, United States, Belgium and 10 more countries
Ages 18+
Pfizer · Sites in Italy, United States, Australia and 9 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
300 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 74 · Phase 3 72 · Phase 4 2
First in 1994; this study’s year is marked. 22 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 200 across 1,436 observational studies indexed under Lung Neoplasms.
Median enrollment 241 across the 206 interventional studies, 200 across the 91 observational. Of the 153 that completed or were terminated, 56 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
141 of 300 have an industry lead sponsor. The 10 most frequent:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 953 studies on the registry; 541 are open to participants now.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS has 7 studies filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
26 of the studies in Lung Neoplasms with a site in Italy that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06151574Phase 3Boehringer IngelheimBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | 2026-12-10 |
| NCT04380636Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | 2027-05-05 |
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06635824Phase 3GenmabTrial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | 2027-07-30 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
Add all 26 to your calendar (.ics) → With an account.
Among the 300 studies in Lung Neoplasms with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The distribution of demographic, clinical, radiological, pathological and molecular characteristics of lung cancer at the time of diagnosis, as well as preferential association between elements of those domains, have not been specifically studied in Italy. The aim of the present project is to assess, in a systematic fashion, the demographic, clinical, radiological, pathological and molecular characteristics of advanced lung cancer at the time of diagnosis in a large Italian cohort of consecutive patients referred to two tertiary referral centers.
Consecutive, treatment-naïve, patients with clinical and radiological suspicion of advanced lung cancer referred for the initial diagnosis/staging/molecular profiling.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Evaluation of the demographic, clinical, histological and molecular characteristics of advanced lung cancer at the time of Diagnosis
Distribution of histologic subtypes
The investigators will assess the prevalence of histologic subtypes in patients with advanced lung cancer
Time frame: 24 months
Distribution of histologic subtypes according to clinical and radiological characteristics
The investigators will assess the prevalence of different histologic subtypes according to clinical and imaging characteristics
Time frame: 24 months
Molecular profiling
Prevalence of individual molecular markers in patients with advanced non-squamous non-small cell lung cancer histology
Time frame: 24 months
Time to diagnosis
Time lag between onset of symptoms (if any) and invasive testing
Time frame: 24 months
Plan to share: Undecided — The investigators will decide how to share the data at the end of the study upon reasonable request to be addressed to the principal investigator.
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for Oct 2026, 35 months after the start.
Of 592 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's planned 35 months is below that.
Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion May 2026 → Oct 2026 and completion Aug 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS →